Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial

ConclusionsThe presence of apparent peritoneal metastasis might be a predictive factor for selecting w-nab-PTX for pretreated AGC patients.Trial registration numberJapicCTI-132059.

Source: Gastric Cancer - May 31, 2018 Category: Gastroenterology Source Type: research